By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Anticancer, Inc. v. Cellsight Technologies, Inc. et al.
3:10-cv-02515; filed December 8, 2010 in the Southern District of California
• Plaintiff: Anticancer, Inc.
• Defendants: Cellsight Technologies, Inc.; Does 1-50
Infringement of U.S. Patent Nos. 6,759,038 ("Metastasis Models Using Green Fluorescent Protein (GFP) As a Marker," issued July 6, 2004) and 6,649,159 ("Whole-body Optical Imaging of Gene Expression and Uses Thereof," issued November 18, 2003) based on Cellsight's offering of its fluorescence optical imaging services. View the complaint here.
Mylan Pharmaceuticals Inc. v. Ethypharm SA et al.
1:10-cv-01064; filed December 7, 2010 in the District Court of Delaware
• Plaintiff: Mylan Pharmaceuticals Inc.
• Defendants: Ethypharm SA; Ethypharm USA Corp.
Declaratory judgment of non-infringement of U.S. Patent No. 6,106,861 ("Multiparticulate Tablet Disintegrating in Less Than 40 Seconds in the Mouth," issued August 22, 2000), licensed to Azur Pharma, following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Azur's FazaClo® (clozapine, used to treat schizophrenia). View the complaint here.
Astellas US LLC et al. v. Nycomed U.S. Inc.
2:10-cv-06326; filed December 7, 2010 in the District Court of New Jersey
• Plaintiffs: Astellas US LLC; Astellas Pharma Inc.
• Defendant: Nycomed U.S. Inc.
Infringement of U.S. Patent Nos. 5,665,727 ("Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene Derivatives and Pharmaceutical Compositions Containing Them," issued September 9, 1997) and 5,385,907 ("Ointments Containing FK-506 or Derivatives Thereof," issued January 31, 1995) following a Paragraph IV certification as part of Nycomed's amendment to its ANDA to manufacture a generic version of Astellas' Protopic® (tacrolimus ointment, used to treat moderate to severe eczema). View the complaint here.
Precision BioSciences, Inc. v. Cellectis SA
5:10-cv-00550; filed December 6, 2010 in the Eastern District of North Carolina
Declaratory judgment of non-infringement of U.S. Patent No. 7,842,489 ("Use of Meganucleases For Inducing Homologous Recombination Ex Vivo and In Toto In Vertebrate Somatic Tissues and Application Thereof," issued November 30, 2010) based on Precision's use of its Directed Nuclease Editor technology. View the complaint here.
Medicis Pharmaceutical Corp. v. Aurobindo Pharma Ltd. et al.
3:10-cv-06318; filed December 6, 2010 in the District Court of New Jersey
• Plaintiff: Medicis Pharmaceutical Corp.
• Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA, Inc.
Infringement of U.S. Patent Nos. 5,908,838 ("Method for the Treatment of Acne," issued June 1, 1999) and 7,790,705 ("Minocycline Oral Dosage Forms for the Treatment of Acne," issued September 7, 2010) following a Paragraph IV certification as part of Aurobindo's filing of an ANDA to manufacture a generic version of Medics' Solodyn® (minocycline hydrochloride extended release tablets, used to treat acne). View the complaint here.
Comments